Merck, Terns Pharmaceuticals receive US antitrust clearance
Drugmaker Merck and oncology medicine developer Terns Pharmaceuticals have received antitrust clearance from the US competition authorities for their $6.7 billion deal. The waiting period under the Hart-Scott-Rodino Act expired on...To view the full article, register now.
Already a subscriber? Click here to view full article